Oscar Health (NYSE:OSCR) Price Target Lowered to $18.00 at Piper Sandler

Oscar Health (NYSE:OSCR) had its price objective trimmed by Piper Sandler from $25.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

OSCR has been the subject of several other reports. Wells Fargo & Company downgraded Oscar Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $20.00 to $16.00 in a research note on Thursday, March 13th. Wall Street Zen lowered shares of Oscar Health from a “buy” rating to a “hold” rating in a research report on Sunday. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $16.50.

Oscar Health Stock Performance

Oscar Health stock opened at $14.77 on Monday. The stock has a market cap of $3.76 billion, a PE ratio of -738.13 and a beta of 1.73. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.26. The business’s 50-day moving average price is $13.90 and its two-hundred day moving average price is $14.52. Oscar Health has a 12-month low of $11.20 and a 12-month high of $23.79.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.09. The firm had revenue of $3 billion for the quarter, compared to the consensus estimate of $2.87 billion. Oscar Health had a net margin of 0.28% and a return on equity of 2.28%. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.62 EPS. As a group, analysts expect that Oscar Health will post 0.69 earnings per share for the current fiscal year.

Insider Activity

In other Oscar Health news, Director Elbert O. Jr. Robinson sold 25,000 shares of Oscar Health stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $16.43, for a total transaction of $410,750.00. Following the sale, the director now directly owns 64,512 shares of the company’s stock, valued at approximately $1,059,932.16. The trade was a 27.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 24.39% of the company’s stock.

Institutional Trading of Oscar Health

Several institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Oscar Health by 348.7% during the 4th quarter. JPMorgan Chase & Co. now owns 10,360,529 shares of the company’s stock valued at $139,246,000 after acquiring an additional 8,051,379 shares during the period. BIT Capital GmbH boosted its position in Oscar Health by 5,711.6% in the fourth quarter. BIT Capital GmbH now owns 4,473,853 shares of the company’s stock worth $60,129,000 after purchasing an additional 4,396,872 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of Oscar Health by 50.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 11,835,000 shares of the company’s stock valued at $159,062,000 after purchasing an additional 3,983,325 shares during the period. Nuveen LLC bought a new position in shares of Oscar Health in the 1st quarter worth approximately $29,684,000. Finally, Gilder Gagnon Howe & Co. LLC grew its holdings in Oscar Health by 51.4% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 6,335,862 shares of the company’s stock valued at $85,154,000 after purchasing an additional 2,151,256 shares during the period. 75.70% of the stock is owned by hedge funds and other institutional investors.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.